文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

随机HERMES试验的中期毒性分析:2次与5次磁共振成像引导自适应前列腺放疗

Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-29

HERMES是一项单中心非比较性随机2期试验,纳入中危或低高危前列腺癌男性,1:1分配至5次36.25 Gy(2周)或2次24 Gy(8天)并对MRI可见肿瘤整合推量27 Gy(2次),采用Unity MR-Linac每日在线自适应放疗。中期分析显示5次组急性2级GU毒性1例(10%),2次组2例(20%),无3级及以上GU毒性;两组GU毒性率均低于预设阈值(5/10例2级及以上),建议继续研究至每组23例完成入组。

要点

  • 5次组急性2级GU毒性1例(10%),2次组2例(20%),均无3级及以上GU毒性。
  • 两组GU毒性率均低于预设阈值(5/10例2级及以上),建议继续入组至每组23例。
  • 治疗采用Unity MR-Linac每日在线自适应,2次组对MRI可见肿瘤整合推量27 Gy(2次)。

核心结论

  • 中期分析时,2次和5次治疗组的GU毒性率均低于预设阈值(5/10例2级及以上),建议继续研究以完成每组23例的入组。

研究设计与样本

  • HERMES为单中心非比较性随机2期试验,纳入中危或低高危前列腺癌男性,1:1分配至5次36.25 Gy(2周)或2次24 Gy(8天)并对MRI可见肿瘤整合推量27 Gy(2次)。
  • 采用含随机要素的最小化算法进行随机化,以风险组作为平衡因素;治疗在Unity MR-Linac(Elekta AB)上实施每日在线自适应。
  • 主要终点为急性GU毒性(CTCAE 5.0版),旨在排除PACE研究中急性2级及以上GU毒性发生率翻倍;分析按实际接受治疗进行,纳入至少接受1次研究治疗的参与者。
  • 本次中期分析为预设的两阶段Simon设计第1阶段,触发条件为每组10例参与者完成急性毒性监测期(放疗后12周)。

主要发现

  • 5次组报告急性2级GU毒性1例(10%),2次组报告2例(20%)。
  • 两组均未报告3级及以上GU毒性。

关键数值与推荐

  • 预设阈值为5/10例2级及以上GU毒性;中期分析时两组GU毒性率均低于该阈值。
  • 建议继续研究以完成每组23例的入组。

局限性

  • 原文为单中心非比较性随机2期试验。
  • 本次为预设的中期分析(两阶段Simon设计第1阶段),触发条件为每组10例完成急性毒性监测期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ultrahypofractionated radiation therapy (UHRT) is an effective treatment for localized prostate cancer with an acceptable toxicity profile; boosting the visible intraprostatic tumor has been shown to improve biochemical disease-free survival with no significant effect on genitourinary (GU) and gastrointestinal (GI) toxicity. METHODS AND MATERIALS: HERMES is a single-center noncomparative randomized phase 2 trial in men with intermediate or lower high risk prostate cancer. Patients were allocated (1:1) to 36.25 Gy in 5 fractions over 2 weeks or 24 Gy in 2 fractions over 8 days with an integrated boost to the magnetic resonance imaging (MRI) visible tumor of 27 Gy in 2 fractions. A minimization algorithm with a random element with risk group as a balancing factor was used for participant randomization. Treatment was delivered on the Unity MR-Linac (Elekta AB) with daily online adaption. The primary endpoint was acute GU Common Terminology Criteria for Adverse Events version 5.0 toxicity with the aim of excluding a doubling of the rate of acute grade 2+ GU toxicity seen in PACE. Analysis was by treatment received and included all participants who received at least 1 fraction of study treatment. This interim analysis was prespecified (stage 1 of a 2-stage Simon design) for when 10 participants in each treatment group had completed the acute toxicity monitoring period (12 weeks after radiation therapy). RESULTS: Acute grade 2 GU toxicity was reported in 1 (10%) patient in the 5-fraction group and 2 (20%) patients in the 2-fraction group. No grade 3+ GU toxicities were reported. CONCLUSIONS: At this interim analysis, the rate of GU toxicity in the 2-fraction and 5-fraction treatment groups was found to be below the prespecified threshold (5/10 grade 2+) and continuation of the study to complete recruitment of 23 participants per group was recommended.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Westley RL, Biscombe K, Dunlop A, et al. Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 37776979. doi:10.1016/j.ijrobp.2023.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。